SBIR/STTR Research Award

ENSYME IMMUNOASSAY FOR 8-ISO-2,3-DINOR PROSTAGLADIN F1

Award identifier 48da6936a4731ed3f09365abd1c076488783a76c7684ee780eb8f0cf6484d779Awarding agency Department of Health and Human Services

Award amount

$99,871

Program and phase

SBIR · Phase I

Award year

1998

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
CAYMAN CHEMICAL COMPANY, INCORPORATED
Proposal award date
Not reported
Contract end date
Not reported
UEI
T1ZHJRGR7TF4
Solicitation number
Not reported
Topic code
NIEHS

Research abstract

The long-term objective of this proposal is the development of a reliable and sensitive assay for the accurate measurement of lipid peroxidation as an index of oxidative stress. The implication of oxidative stress in atherosclerosis, ischemia-reperfusion injury, inflammation, cancer, and aging highlights the importance of establishing methodology for the measurement of a reliable market or peroxidative injury. Recent identification of 8-iso-2,3-dinor PGF1alpha as a reliable marker of lipid peroxidation makes it an ideal target for the development of an immunoassay. Specific antibodies that recognize 8-iso-2,3-dinor PGF1alpha are vital for the development of an immunoassay. Antibody development is the primary objective of the present proposal. This will be achieved by a) the synthesis of large quantities of 8-iso-2,3-dinor PGF1alpha and transforming it into a structural analog, b) conjugating 8-iso-2,3-dinor PGF1alpha and its structural analog to a carrier protein, c) injecting in to rabbits and mice, and d) screening the antisera for specific antibodies using an acetylcholinesterase conjugate of 8-iso-2,3-dinor PGF1alpha. Discernable titers of the antibody for 8-iso-2,3-dinor PGF1alpha are expected towards the end of the Phase I contract period. Any highly specific polyclonal antibodies obtained from rabbits will be used for the development of an enzyme immunoassay. Mice producing high titer antisera will be used to develop monoclonal antibodies.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (1998–2025). Reported award amounts total $5,323,029. Reported amounts are not federal obligations.

Phases: Phase I, Phase II – Direct to Phase II, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.